Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | OTLK |
---|---|---|
09:32 ET | 3010 | 7.49 |
09:36 ET | 545 | 7.38 |
09:38 ET | 883 | 7.41 |
09:41 ET | 1023 | 7.445 |
09:45 ET | 655 | 7.41 |
09:48 ET | 5698 | 7.5 |
09:54 ET | 200 | 7.49 |
09:57 ET | 100 | 7.495 |
09:59 ET | 100 | 7.5 |
10:01 ET | 352 | 7.525 |
10:03 ET | 440 | 7.5127 |
10:06 ET | 511 | 7.52 |
10:08 ET | 266 | 7.55 |
10:10 ET | 604 | 7.56 |
10:12 ET | 682 | 7.6099 |
10:14 ET | 700 | 7.6 |
10:15 ET | 1105 | 7.67 |
10:17 ET | 100 | 7.69 |
10:21 ET | 300 | 7.65 |
10:24 ET | 1392 | 7.65 |
10:28 ET | 350 | 7.69 |
10:30 ET | 100 | 7.67 |
10:32 ET | 433 | 7.662 |
10:33 ET | 1252 | 7.65 |
10:37 ET | 100 | 7.6 |
10:39 ET | 1856 | 7.7 |
10:42 ET | 954 | 7.7 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Outlook Therapeutics Inc | 176.2M | -0.7x | --- |
Trevi Therapeutics Inc | 178.9M | -7.4x | --- |
Atossa Therapeutics Inc | 183.6M | -6.3x | --- |
Greenwich Lifesciences Inc | 168.4M | -19.3x | --- |
Achieve Life Sciences Inc | 185.8M | -4.3x | --- |
Kodiak Sciences Inc | 163.4M | -0.7x | --- |
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $176.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 23.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.66 |
EPS | $-11.48 |
Book Value | $-1.11 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.